Ami Vijay Desai, MD
Three patients with targeted gene fusions responded to the multikinase inhibitor entrectinib (RXDX-101), according to results from an ongoing phase I/Ib study of children and young adults with advanced, previously treated CNS tumors.
, Desai discussed the ideal patient population for entrectinib and what the future could hold for the agent.
OncLive: Can you provide some insight into the rationale and design of this trial?
We know there are some myosarcomas and various other types of tumors that do have our gene fusions of interest, and a lot of this initial study was developed due to some preclinical data in the neuroblastoma population also looking at TRKB overexpression and work conducted in the laboratory of Dr Garrett M. Brodeur at the Children's Hospital of Philadelphia.
... to read the full story